PMV Pharmaceuticals Inc（PMVP）财务数据PMVPPMV Pharmaceuticals Inc

Evaluating the bottom line, Pmv Pharmaceuticals, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.93%, provide a clear picture of how effectively PMVP converts its operational activities into shareholder value.

In the context of the broader market, PMVP competes directly with industry leaders such as KZIA and IMDX. With a market capitalization of $94.77M, it holds a significant position in the sector. When comparing efficiency, PMVP's gross margin of N/A stands against KZIA's 100.00% and IMDX's 65.69%. Such benchmarking helps identify whether Pmv Pharmaceuticals, Inc is trading at a premium or discount relative to its financial performance.

PMV Pharmaceuticals has reported consistent net losses, with a net income of -23 million USD in Q4 2024 and a deteriorating financial outlook, including a net loss of 77.7 million USD for 2025. The current ratio remains strong at 7.70, indicating good short-term financial health despite losses.